Literature DB >> 33363203

Phosphatase and Tensin Homolog Mutation in Immune Cell Infiltration and Clinicopathological Features of Low-Grade Gliomas.

Peng Feng1, Zhenqing Li2, Yuchen Li3, Yuelin Zhang1.   

Abstract

The mutation of phosphatase and tensin homolog (PTEN) genes frequently occur in low-grade gliomas (LGGs) and are deeply associated with a poor prognosis and survival rate. In order to identify the crucial signaling pathways and genes associated with the PTEN mutation, we performed bioinformatics analysis on the RNA sequencing results, which were obtained from The Cancer Genome Atlas database. A total of 352 genes were identified as differentially expressed genes (DEGs). The gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis suggested that the DEGs were significantly enriched in categories associated with cell division and multiple metabolic progressions. The histological stage was significantly associated with PTEN expression levels. In addition, the PTEN mutation was associated with an abundance of B cells, neutrophils, macrophages, dendritic cells, and CD8+ T cells during tumor infiltration. The results showed that patients with LGGs harboring the PTEN mutation had a poor prognosis and more serious immune cell infiltration occurred depending on the mRNA expression level. These results demonstrated that multiple genes and signaling pathways play a key role in LGG from low grade to high grade, and are associated with PTEN mutations. In this study, we outlined an approach to assess the influence of PTEN mutations on prognosis, overall survival, and messenger RNA (mRNA) expression. Our results provided alternative strategies for the personalized treatment of patients with LGGs harboring the PTEN mutation.
Copyright © 2020 Feng, Li, Li and Zhang.

Entities:  

Keywords:  gene; low-grade gliomas; mutation; phosphatase and tensin homolog; prognosis

Year:  2020        PMID: 33363203      PMCID: PMC7758504          DOI: 10.3389/fmolb.2020.562416

Source DB:  PubMed          Journal:  Front Mol Biosci        ISSN: 2296-889X


  28 in total

1.  DAVID: Database for Annotation, Visualization, and Integrated Discovery.

Authors:  Glynn Dennis; Brad T Sherman; Douglas A Hosack; Jun Yang; Wei Gao; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-04-03       Impact factor: 13.583

2.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

Authors:  Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran
Journal:  N Engl J Med       Date:  2016-04-07       Impact factor: 91.245

3.  Glioblastoma survival in the United States before and during the temozolomide era.

Authors:  Derek R Johnson; Brian Patrick O'Neill
Journal:  J Neurooncol       Date:  2011-11-02       Impact factor: 4.130

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

6.  Multidrug resistance proteins expression in glioma patients with epilepsy.

Authors:  Chiara Calatozzolo; Bianca Pollo; Andrea Botturi; Loredana Dinapoli; Mariantonia Carosi; Andrea Salmaggi; Marta Maschio
Journal:  J Neurooncol       Date:  2012-07-26       Impact factor: 4.130

7.  Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.

Authors:  Sarah A Best; David P De Souza; Ariena Kersbergen; Antonia N Policheni; Saravanan Dayalan; Dedreia Tull; Vivek Rathi; Daniel H Gray; Matthew E Ritchie; Malcolm J McConville; Kate D Sutherland
Journal:  Cell Metab       Date:  2018-03-08       Impact factor: 27.287

8.  Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation.

Authors:  Davis J McCarthy; Yunshun Chen; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2012-01-28       Impact factor: 16.971

9.  Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer.

Authors:  Y Ino; R Yamazaki-Itoh; K Shimada; M Iwasaki; T Kosuge; Y Kanai; N Hiraoka
Journal:  Br J Cancer       Date:  2013-02-05       Impact factor: 7.640

10.  LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway.

Authors:  Maolin Mu; Wanxiang Niu; Xiaoming Zhang; Shanshan Hu; Chaoshi Niu
Journal:  Oncogene       Date:  2020-09-25       Impact factor: 8.756

View more
  1 in total

1.  Uncovering the Immune Cell Infiltration Landscape in Low-Grade Glioma for Aiding Immunotherapy.

Authors:  Youyuan Yang; Yue Tian; Qing Li; Rui Jiang; Junfeng Zhang
Journal:  J Oncol       Date:  2022-03-11       Impact factor: 4.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.